-
Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal
•
Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the Swedish rare disease drug firm Calliditas Therapeutics AB (STO: CALTX). Both companies’ boards have approved the deal, with Asahi Kasei proposing to purchase all outstanding public shares of Calliditas at a price of SEK 416…
-
Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy
•
Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new biomarker and subgroup analyses for Nefecon, a targeted oral formulation of budesonide currently under clinical development for the treatment of IgA nephropathy (IgAN). The data was showcased during both poster and oral presentations at the…
